Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis.
Ratings
0 / 5
0 ratings in the last 12 months
5
4
3
2
1
CEO
Ms. Jennifer L. Good$184.8M
Market Cap • 18/04/20242011
(há 13 anos)
2019
(5 years ago)
NASDAQ
Listagem
New Haven
Sede • Connecticut25
N° de Empregados • 2022Valuation
Company FinancialsValuation Indicators
Valuation IndicatorsRetorno Histórico
TRVISó no Premium...
Visualize o retorno de longo prazo das ações. Dividendos e outros eventos são considerados.